PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Through this study, the investigators are to prove that Cilostazol effectively prevent
cardiovascular events in ischemic stroke patients with high risk of cerebral hemorrhage,
along with no significant increase in the risk of occurrence of hemorrhagic side effects.
The primary hypothesis of this study is; Cilostazol alone or with probucol will reduce the
risk of cerebral hemorrhage without increase of cardiovascular events compared to aspirin in
the ischemic stroke patients with symptomatic or asymptomatic old cerebral hemorrhage.
This study will prove the superiority of cilostazol on the prevention of cerebral hemorrhagic
events without increasing the cardiovascular events against aspirin and the superiority of
probucol on the prevention of overall cardiovascular events.